Top

Published in:

01-02-2012 | Original paper

Serum insulin-like growth factors and mortality in localised and advanced clinically detected prostate cancer

Authors: Mari-Anne Rowlands, Jeff M. P. Holly, Freddie Hamdy, Joshua Phillips, Louise Goodwin, Gemma Marsden, David Gunnell, Jenny Donovan, David E. Neal, Richard M. Martin

Published in: Cancer Causes & Control | Issue 2/2012

Abstract

Context

Many studies have reported associations of insulin-like growth factors (IGFs) and IGF-binding proteins (IGFBPs) with prostate cancer development, but none have investigated their association with fatal progression of prostate cancer.

Objective

We investigated associations of circulating IGF-I, IGF-II, IGFBP-2 and IGFBP-3 with all-cause and prostate cancer mortality in men with clinically identified prostate cancer, stratified by whether localised (stage T1 or T2) or advanced (T3, T4, N1 or M1) at diagnosis.

Design, setting and participants

UK hospital-based cohort study of 396 men with prostate cancer, diagnosed between 1990 and 2008, with mean follow-up of 3.7 years.

Main outcome measures

All-cause and prostate cancer–specific mortality.

Results

In men with advanced cancer, there was some evidence that IGF-I was positively associated (HR 1.20; 95% CI: 0.96, 1.49; p = 0.11) and IGFBP-3 was inversely associated (HR 0.84; 95% CI: 0.70, 1.01; p = 0.07) with all-cause mortality after controlling for age, treatment status, smoking, prostate-specific antigen and Gleason grade at diagnosis. There was some evidence that IGF-I was positively associated with prostate cancer mortality in advanced cases (HR 1.23; 95% CI: 0.94, 1.62; p = 0.13). In advanced cancers, associations of IGF-I with all-cause (HR 1.68; 95% CI: 1.28, 2.23; p < 0.001) and prostate cancer–specific (HR 1.59; 95% CI: 1.11, 2.28; p = 0.01) mortality strengthened (and were conventionally statistically significant) after further controlling for IGFBP-3.

Conclusions

Measures of IGF-I and IGFBP-3 may have potential as prognostic markers in predicting risk of death in men with advanced prostate cancer. Large, prospective studies with repeat IGFs and IGFBPs are now required.

Parkin DM, Bray FI, Devesa SS (2001) Cancer burden in the year 2000. The global picture. Eur J Cancer 37:4–66CrossRef

Johansson JE, Holmberg L, Johansson S, Bergstrom R, Adami HO (1997) Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA 277:467–471PubMedCrossRef

Concato J, Jain D, Uchio E, Risch H, Li WW, Wells CK (2009) Molecular markers and death from prostate cancer. Ann Intern Med 150:595–603PubMed

Fall K, Garmo H, Andren O, Bill-Axelson A, Adolfsson J, Adami HO, Johansson JE, Holmberg L (2007) Prostate-specific antigen levels as a predictor of lethal prostate cancer. JNCI J Natl Cancer Inst 99:526–532CrossRef

Metcalfe C, Tilling K, Davis M, Lane JA, Martin RM, Kynaston H, Powell P, Neal DE, Hamdy F, Donovan JL (2009) Current strategies for monitoring men with localised prostate cancer lack a strong evidence base: observational longitudinal study. Br J Cancer 101:390–394PubMedCrossRef

Pollak M (2008) Insulin, insulin-like growth factors and neoplasia. Best Pract Res Clin Endocrinol Metab 22:625–638PubMedCrossRef

Rowlands M, Gunnell D, Harris R, Vatten LJ, Holly JMP, Martin RM (2009) Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review and meta-analysis. Int J Cancer 124:2416–2429PubMedCrossRef

Roddam AW, Allen NE, Appleby P, Key TJ, Ferrucci L, Carter HB, Metter EJ, Chen C, Weiss NS, Fitzpatrick A, Hsing AW, Lacey JV Jr, Helzlsouer K, Rinaldi S, Riboli E, Kaaks R, Janssen JAMJ, Wildhagen MF, Schroder FH, Platz EA, Pollak M, Giovannucci E, Schaefer C, Quesenberry CP Jr, Vogelman JH, Severi G, English DR, Giles GG, Stattin P, Hallmans G, Johansson M, Chan JM, Gann P, Oliver SE, Holly JM, Donovan J, Meyer F, Bairati I, Galan P (2008) Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med 149:461–471PubMed

Petridou E, Salkidou A, Dessypris N, Moustaki M, Mantzoros C, Spanos E, Trichopoulos D (2001) Insulin-like growth factor binding protein-3 predicts survival from acute childhood leukemia. Oncology 60:252–257PubMedCrossRef

10.

Rocha RL, Hilsenbeck SG, Jackson JG, VanDenBerg CL, Weng C, Lee AV, Yee D (1997) Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: correlation with clinical parameters and disease-free survival. Clin Cancer Res 3:103–109PubMed

11.

Wakai K, Ito Y, Suzuki K, Tamakoshi A, Seki N, Ando M, Ozasa K, Watanabe Y, Kondo T, Nishino Y, Ohno Y (2002) Serum insulin-like growth factors, insulin-like growth factor-binding protein-3, and risk of lung cancer death: a case-control study nested in the Japan Collaborative Cohort (JACC) Study. Jpn J Cancer Res 93:1279–1286PubMedCrossRef

12.

Yu H, Levesque MA, Khosravi MJ, Papanastasiou-Diamandi A, Clark GM, Diamandis EP (1998) Insulin-like growth factor binding protein-3 and breast cancer survival. Int J Cancer 79:624–628PubMedCrossRef

13.

Parker AS, Cheville JC, Lohse C, Cerhan JR, Blute ML (2003) Expression of insulin-like growth factor I receptor and survival in patients with clear cell renal cell carcinoma. J Urol 170:420–424PubMedCrossRef

14.

Lin Y, Tamakoshi A, Kikuchi S, Yagyu K, Obata Y, Ishibashi T, Kawamura T, Inaba Y, Kurosawa M, Motohashi Y, Ohno Y (2004) Serum insulin-like growth factor-I, insulin-like growth factor binding protein-3, and the risk of pancreatic cancer death. Int J Cancer 110:584–588PubMedCrossRef

15.

Vadgama JV, Wu Y, Datta G, Khan H, Chillar R (1999) Plasma insulin-like growth factor-I and serum IGF-binding protein 3 can be associated with the progression of breast cancer, and predict the risk of recurrence and the probability of survival in African-American and Hispanic women. Oncology 57:330–340PubMedCrossRef

16.

Greene FL, Page DL (2002) Genitourinary sites. Prostate. In: Green FL, Page DL, Fleming ID, Fritz AD, Balch CM, Haller DG, Morrow M (eds) AJCC cancer staging manual. Springer, New York, pp 309–317

17.

Juul A, Main K, Blum WF, Lindholm J, Ranke MB, Skakkebaek NE (1994) The ratio between serum levels of insulin-like growth factor (IGF)-I and the IGF binding proteins (IGFBP-1, 2 and 3) decreases with age in healthy adults and is increased in acromegalic patients. Clin Endocrinol 41:85–93CrossRef

18.

Holly J, Perks C (2006) The role of insulin-like growth factor binding proteins. Neuroendocrinology 83:154–160PubMedCrossRef

19.

Fukuda R, Hirota K, Fan F, Jung YD, Ellis LM, Semenza GL (2002) Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem 277:38205–38211PubMedCrossRef

20.

Playford MP, Bicknell D, Bodmer WF, Macaulay VM (2000) Insulin-like growth factor 1 regulates the location, stability, and transcriptional activity of B-catenin. Proc Natl Acad Sci USA 97:12103–12108PubMedCrossRef

21.

Jones JI, Clemmons D (1995) Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 16:3–34PubMed

22.

Satariano WA, Ragland KE, Van Den Eeden SK (1998) Cause of death in men diagnosed with prostate carcinoma. Cancer 83:1180–1188PubMedCrossRef

23.

Friedrich N, Haring R, Nauck M, Ludemann J, Rosskopf D, Spilcke-Liss E, Felix SB, Dorr M, Brabant G, Volzke H, Wallaschofski H (2009) Mortality and serum insulin-like growth factor (IGF)-I and IGF binding protein 3 concentrations. J Clin Endocrinol Metab 94:1732–1739PubMedCrossRef

24.

Yu H, Rohan T (2000) Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 92:1472–1489PubMedCrossRef

25.

Lawlor DA, Ebrahim S, Smith GD, Cherry L, Watt P, Sattar N (2008) The association of insulin-like-growth factor 1 (IGF-1) with incident coronary heart disease in women: findings from the prospective British Women’s Heart and Health Study. Atherosclerosis 201:198–204PubMedCrossRef

26.

Goodman-Gruen D, Barrett-Connor E (1997) Epidemiology of insulin-like growth factor-I in elderly men and women: the rancho bernardo study. Am J Epidemiol 145:970–976PubMed

27.

Botker HE, Skjaerbaek C, Eriksen UK, Schmitz O, Orksov H (1997) Insulin-like growth factor-I, insulin, and angina pectoris secondary to coronary atherosclerosis, vasospasm, and syndrome X. Am J Cardiol 79:961–963PubMedCrossRef

28.

Sandhu MS (2005) Insulin-like growth factor-l and risk of type 2 diabetes and coronary heart disease: molecular epidemiology. Endocr Dev 9:44–54PubMedCrossRef

29.

Rowlands M-A, Holly J, Gunnell D, Gilbert R, Donovan J, Lane J, Marsden G, Collin S, Hamdy F, Neal D, Martin R (2010) The relation between adiposity throughout the life course and variation in IGFs and IGFBPs: evidence from the ProtecT (Prostate testing for cancer and Treatment) study. Cancer Causes Control 21:1842CrossRef

30.

Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M (1998) Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279:563–566PubMedCrossRef

31.

Platz EA, Pollak MN, Leitzmann MF, Stampfer MJ, Willett WC, Giovannucci E (2005) Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era. Cancer Causes Control 16:255–262PubMedCrossRef

32.

Thissen J-P, Ketelslegers J-M, Underwood LE (1994) Nutritional regulation of the insulin-like growth factors. Endocr Rev 15:80–101PubMed

33.

Pollak M (2008) Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8:915–928PubMedCrossRef

Title: Serum insulin-like growth factors and mortality in localised and advanced clinically detected prostate cancer
Authors: Mari-Anne Rowlands
Jeff M. P. Holly
Freddie Hamdy
Joshua Phillips
Louise Goodwin
Gemma Marsden
David Gunnell
Jenny Donovan
David E. Neal
Richard M. Martin
Publication date: 01-02-2012
Publisher: Springer Netherlands
Published in: Cancer Causes & Control / Issue 2/2012
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-011-9883-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Context

Objective

Design, setting and participants

Main outcome measures

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2012

Being breastfed in infancy and adult breast cancer risk among Japanese women

Risk of esophageal cancer in diabetes mellitus: a meta-analysis of observational studies

Adverse events after screening and follow-up colonoscopy

Does hormone replacement therapy and use of oral contraceptives increase the risk of non-melanoma skin cancer?

Serum levels of 25-hydroxyvitamin D and survival in Norwegian patients with cancer of breast, colon, lung, and lymphoma: a population-based study

Measured body mass index in adolescence and the incidence of pancreatic cancer in a cohort of 720,000 Jewish men

Keynote webinar | Spotlight on antibody–drug conjugates in cancer